Navigation Links
Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
Date:5/29/2012

SEATTLE, May 29, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) will host an investor and analyst meeting to discuss unmet medical needs and targeted agents in myelofibrosis and high-risk myelodysplastic syndrome/acute myeloid leukemia, including data from pacritinib, the product candidate that CTI has agreed to acquire, and CTI's product candidate tosedostat. The event will take place on Sunday, June 3, 2012 in Chicago, Illinois.  The American Society of Clinical Oncology Annual Meeting is being held in Chicago from June 1-5, 2012.

Speakers at the event will include: Srdan Verstovsek, M.D., Ph.D., MD Anderson Cancer Center, Houston, Texas; Elihu Estey, M.D., Seattle Cancer Care Alliance, Seattle, Wash., Rami Komrokji, M.D., Moffitt Cancer Center, Tampa, Fla.; and David Steensma, M.D., F.A.C.P., Dana-Farber Cancer Institute, Boston, Mass.

The presentations will begin at 7 a.m. CDT /8 a.m. EDT /5 a.m. PDT /2 p.m. CET and conclude at approximately 8 a.m. CDT /9 a.m. EDT /6 a.m. PDT /3 p.m. CET. The presentations will be webcast live with slides and archived at www.celltherapeutics.com.

About Pacritinib

Pacritinib is an oral, once a day, tyrosine kinase inhibitor (TKI) with dual activity against JAK2 and FMS-like tyrosine kinase 3 (FLT3). Mutations in these kinases have been shown to be directly related to the development of a variety of blood related cancers including MPD, leukemia and lymphoma. Pacritinib has demonstrated encouraging results in phase 1 and 2 studies for patients with myelofibrosis and a phase 3 study is planned in this disease.

FLT3 is a commonly mutated gene found in acute myeloid leukemia (AML) patients and its activating mutations have been proven to be a negative prognostic marker for clinical outcome suggesting a possible future role for treatment of AML.

About Tosedostat

Tosedostat is an ora
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
2. Echo Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
4. Jim DuCharme Joins Prime Therapeutics as Chief Financial Officer
5. Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
6. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
7. Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
8. Nile Therapeutics Reports 2012 First Quarter Financial Results
9. Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in Gastroenterology Portfolio
10. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
11. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ATLANTA , Sept. 30, 2014  Georgia-Pacific ... systems, towels and tissue for a wide range ... success of its product lines in healthcare, including ... practices, Georgia-Pacific Professional is introducing its healthcare products ... "Georgia-Pacific Professional understands the importance of infection control ...
(Date:9/30/2014)... 30, 2014   Decision Resources Group finds ... anemic chronic kidney disease non-dialysis (CKD-ND) patients are ... medication. In addition, one-year persistency is similar between ... Other key findings from the report entitled ... Erythropoiesis Stimulating Agents in Late Stage Chronic Kidney ...
(Date:9/30/2014)... , Sept. 30, 2014   Acutus ... minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole ... and / or sustain complex cardiac arrhythmias, including atrial ... to continue developing its imaging/mapping system as well as ... will allow Acutus Medical to complete work on the ...
Breaking Medicine Technology:Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... NEW YORK, Oct. 7 Reportlinker.com announces that ... its catalogue: U.S. Venous Access ... This study covers U.S. markets for ... (PICCs), central venous catheters (CVCs), dialysis catheters, implantable ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix, today announced that it will host a ... in New York. During the meeting, Halozyme,s management will ... business alliances with Roche and Baxter, and an update ...
Cached Medicine Technology:Reportlinker Adds U.S. Venous Access Catheter Market 2Reportlinker Adds U.S. Venous Access Catheter Market 3Reportlinker Adds U.S. Venous Access Catheter Market 4Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York 2
(Date:9/30/2014)... Orem, Utah (PRWEB) September 30, 2014 A ... at Ohio State University studied the impact of stress on ... patty burger and french fries from a fast food restaurant, ... each woman’s resting metabolism for 20 minutes every hour for ... , Results showed that women who had experienced a stressful ...
(Date:9/30/2014)... PHILADELPHIA Federally Qualified Health Centers (FQHCs) granted ... patients at higher rates than other primary care ... visits, according to results of a new 10-state ... Medical Care . , Using data from ... and 2013, the investigators found that FQHCs ...
(Date:9/30/2014)... Maryland-led research team has been awarded a three-year ... Health (NIH) to develop new imaging technologies and ... of how large networks of neurons in the ... will help researchers identify the precise interactions between ... decision-making and speaking, and alterations in these interactions ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 Fat ... nutrition specialist and best-selling author Mike Geary that is helping ... transform their body into a fat-burning machine in less than ... an investigative review. , “In our culture that is ... be hard to decipher what is really fact and fiction ...
(Date:9/30/2014)... VisitandCare.com reports that revenue for ... more than 79 percent in 2014, marking five straight ... total revenue tripled for its entirety of partnered medical ... has allowed them to partner with plastic surgery ... and privacy — with state-of-the-art surgical atmospheres aimed to ...
Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... Disabled American,Veteran, Eric V. Trager, along with business ... Durant Management Corporation, announced,the development of a non-profit ... The purpose of AVHRT is to provide housing, ... with a strong focus on,the needs of disabled ...
... BioTech Inc. (OTC,Bulletin Board: PLMO.OB) has announced the ... Imaging technology., The PulmoBind product candidates being ... allow the imaging of the vascular,system of the ... the diagnosis,of Pulmonary Embolism, Pulmonary Hypertension and Lung ...
... release of Human right commission of Pakistan July 2nd ... following release is,being issued by the Ahmadiyya Muslim Community ... of Jamaat Islami) have,tried to spread unrest to other ... three Ahmadi female students were locked,up in their rooms ...
... aureus (MRSA) for long periods of time continue to ... according to a new study in the July 15 ... online. , MRSA is an antibiotic-resistant bacterium that can ... commonly colonizes the nostrils, although it can be found ...
... 2 The legacy of caring begun 29,years ago by ... of the area,s,most significant Summer fundraisers, thanks to the enthusiastic ... for low-income families,just starting out., The 29th annual Twilight ... Thursday, July 10 from 5:30-8 p.m. at the home,of WCP ...
... SMITHFIELD, R.I., July 2 FGX International,(Nasdaq: ... non-prescription reading,glasses, sunglasses and costume jewelry, today announced ... and Anthony DiPaola, Chief,Financial Officer will be presenting ... Tuesday, July 8, 2008 at The Four Seasons ...
Cached Medicine News:Health News:Disabled Veteran Establishes Non-Profit, AVHRT, to House Injured Veterans 2Health News:Pulmo BioTech Inc. Announces Possibility of MRI Application for PulmoBind 2Health News:Pulmo BioTech Inc. Announces Possibility of MRI Application for PulmoBind 3Health News:Being an MRSA carrier increases risk of infection and death 2Health News:Area Women Gather in Milford on July 10 to Further the Mission of Women's Caring Program 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: